OnKure Therapeutics, Inc. OKUR Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by OnKure Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about OnKure Therapeutics, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OnKure Therapeutics, Inc.'s operating lease right-of-use asset amortization?
- OnKure Therapeutics, Inc. (OKUR) reported operating lease right-of-use asset amortization of $99K in Q1 2026.
- How has OnKure Therapeutics, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- OnKure Therapeutics, Inc.'s operating lease right-of-use asset amortization increased by 5.3% year-over-year, from $94K to $99K.
- What is the long-term trend for OnKure Therapeutics, Inc.'s operating lease right-of-use asset amortization?
- Over 2 years (2023 to 2025), OnKure Therapeutics, Inc.'s operating lease right-of-use asset amortization has grown at a 63.7% compound annual growth rate (CAGR), from $143K to $383K.